- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04700202
Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
February 23, 2023 updated by: Methodist Health System
Single center, retrospective chart review.
Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Single center, retrospective chart review.
Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
Patients with respiratory culture data signifying a Gram-negative organism as the cause of HAP/VAP will be analyzed as described below if study inclusion criteria is met.
Minimum inhibitory concentration (MIC) data will interpreted per Clinical & Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance.
Multivariable logistic regression will be performed to determine risk factors for piperacillin-tazobactam, cefepime or meropenem resistant Gram-negative isolates.
Project target date of completion and close-out is May 2021.
Study Type
Observational
Enrollment (Actual)
132
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Methodist Dallas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
Description
Inclusion Criteria:
- ICU, Neuro critical care unit admission
- Diagnosis of HAP or VAP
- Respiratory culture positive for Gram-negative organism
Exclusion Criteria:
- ICU length of stay <48 hours prior to HAP/VAP
- Culture or MIC data unavailable
- Pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Retrospective Cohort
Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
|
Single center, retrospective chart review.
Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Gram-negative isolate resistance to piperacillin-tazobactam, cefepime, meropenem
Time Frame: April 2017 - May 2020
|
Percentage
|
April 2017 - May 2020
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of susceptibility to non-beta lactam antipseudomonal agents
Time Frame: April 2017 - May 2020
|
Percentage
|
April 2017 - May 2020
|
in-hospital mortality
Time Frame: April 2017 - May 2020
|
Percentage
|
April 2017 - May 2020
|
need for mechanical ventilation
Time Frame: April 2017 - May 2020
|
Percentage
|
April 2017 - May 2020
|
duration of mechanical ventilation
Time Frame: April 2017 - May 2020
|
number of days
|
April 2017 - May 2020
|
development of septic shock
Time Frame: April 2017 - May 2020
|
Percentage
|
April 2017 - May 2020
|
ICU length of stay
Time Frame: April 2017 - May 2020
|
number of days
|
April 2017 - May 2020
|
hospital length of stay
Time Frame: April 2017 - May 2020
|
number of days
|
April 2017 - May 2020
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 30, 2020
Primary Completion (Actual)
December 15, 2022
Study Completion (Actual)
December 15, 2022
Study Registration Dates
First Submitted
September 22, 2020
First Submitted That Met QC Criteria
January 6, 2021
First Posted (Actual)
January 7, 2021
Study Record Updates
Last Update Posted (Estimate)
February 27, 2023
Last Update Submitted That Met QC Criteria
February 23, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 046.PHA.2020.D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hospital-acquired Pneumonia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical MedicineCompletedCommunity Acquired Pneumonia | Lower Respiratory Tract Infection | Hospital Acquired PneumoniaUnited Kingdom
-
PfizerCompletedHospital-Acquired PneumoniaChina
-
University of BirminghamHeart of England NHS TrustCompletedHospital Acquired PneumoniaUnited Kingdom
-
University Hospital OlomoucPalacky UniversityCompletedHospital Acquired Pneumonia
-
Nantes University HospitalNot yet recruitingHospital Acquired PneumoniaFrance
-
Assiut UniversityUnknownPneumonia Hospital AcquiredEgypt
-
PfizerRecruitingHospital Acquired Pneumonia | Complicated Intra Abdominal Infections | Ventilator Acquired PneumoniaChina
Clinical Trials on Observational
-
University of MinnesotaAgency for Healthcare Research and Quality (AHRQ)RecruitingTraumatic Brain Injury | Venous ThromboembolismUnited States
-
American Gastroenterological AssociationUniversity of Pennsylvania; University of California, San Diego; University of... and other collaboratorsRecruitingClostridium Difficile Infection | Gut Microbiome | Fecal Microbiota TransplantationUnited States, Canada
-
Massachusetts General HospitalRecruiting
-
Taysha Gene Therapies, Inc.Withdrawn
-
University Hospital, AntwerpUniversiteit AntwerpenUnknownType 1 Diabetes | Diastolic Dysfunction | Coronary Artery CalcificationsBelgium
-
St. Louis UniversityActive, not recruitingVertebral Artery StenosisUnited States
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain